The Effect of Prematurity and Hypertensive Disorders of Pregnancy on Offspring Cardiovascular Health (EPOCH)
研究概览
详细说明
While the incidence of cardiovascular disease has reduced dramatically, coinciding with favourable changes in risk factors, cardiovascular disease remains the single largest cause of mortality and premature mortality in the United Kingdom. Identification of novel biological pathways that underlie disease susceptibility raises the potential for new early primary prevention strategies to complement classical management. There is particular interest in the role of early environment in 'programming' risk of cardiovascular disease in later life and growing evidence that various early life exposures impact cardiovascular health in the longer term.
The investigators have therefore designed the EPOCH study to investigate whether those individuals born to hypertensive pregnancies and/or to a preterm birth demonstrate differences in the cardiovascular phenotype at birth, or whether they develop any differences over the first three months of life and whether this varies with other perinatal factors. This study also allows investigation of the short term impact of perinatal interventions used in this cohort. Comprehensive multi-modality non-invasive imaging measures of cardiovascular structure and function allow precise quantification of cardiovascular phenotype in this population.
研究类型
注册 (预期的)
联系人和位置
学习地点
-
-
Oxfordshire
-
Oxford、Oxfordshire、英国、OX3 9DU
- 招聘中
- Cardiovascular Clinical Research Facility, Dept of Cardiovascular Medicine, University of Oxford
-
接触:
- Paul Leeson, PhD, MRCP
- 邮箱:paul.leeson@cardiov.ox.ac.uk
-
首席研究员:
- Paul Leeson, PhD, FRCP
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- Available for assessment within the neonatal period,
- Parent is willing and able to give informed consent for participation in the study,
- Physical condition is suitable to allow non-invasive vascular testing,
- Mother meets criteria for inclusion in the study and is willing to participate in the study. (Aged >/= 16 years and Is able and willing to give informed consent for participation in the study, and is able and willing to give informed consent for her infants participation in the study. )
- Cases: Diagnosed during pregnancy with preeclampsia or gestational hypertension and/or delivered preterm (<37 weeks gestation)
- Controls: No history of gestational hypertension or preeclampsia during this pregnancy and delivered at term (>37 weeks gestation)
Exclusion Criteria:
- Parent is unwilling to give consent,
- Unavailable for assessment of cardiovascular system,
- Physical condition unsuitable to allow for non-invasive testing of cardiovascular system,
- Evidence of congenital cardiovascular disease (with the exception of Persistent Patent Ductus Arterious (PDA) and Atrial Septal Defect (ASD)),
- Cardiorespiratory instability at time of proposed measures,
- Active infection at time of proposed study measures,
- Mother of infant is excluded from the study. (Aged <16 years, unable or unwilling to consent to study or Physical condition post delivery such that it would preclude participation in the study)
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
|---|
|
Normotensive Term
Infants born at term (>37 weeks) to Normotensive pregnancies
|
|
Term Preeclampsia
Infants born at term (>37 weeks gestation) and exposed to a preeclamptic pregnancy
|
|
Preterm Normotensive
Infants born to Normotensive pregnancies at <37 weeks gestation
|
|
Preterm Hypertensive
Infants born to hypertensive pregnancies at <37 weeks completed gestation
|
|
Term Pregnancy-induced Hypertension
Infants born at term (>37 weeks gestation) and exposed to pregnancy-induced hypertension
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Systolic Cardiac Function
大体时间:Birth and 3 months
|
Cardiac Function will be assessed by ECHO at birth and 3 months
|
Birth and 3 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Micro-vascular Structure
大体时间:Birth and 3 months
|
Micro-vascular Structure will be assessed using Side Stream Dark Field (SDF) imaging device at birth and 3 months (as capillary density at baseline)
|
Birth and 3 months
|
|
Pulse wave velocity and pulse-wave analysis
大体时间:Birth and 3 months
|
Birth and 3 months
|
|
|
Cardiac Structure
大体时间:Birth and 3 months
|
Cardiac structure will be assessed by echocardiography at in utero, at birth and 3 months (as left and right ventricular mass)
|
Birth and 3 months
|
|
Cardiac diastolic function
大体时间:Birth and 3 months
|
Cardiac Function will be assessed by ECHO at birth and 3 months
|
Birth and 3 months
|
|
Blood pressure
大体时间:Birth and 3 months
|
Birth and 3 months
|
|
|
Heart rate variability
大体时间:Birth and 3 months
|
Heart rate variability will be assessed by a 5 minute electrocardiogram
|
Birth and 3 months
|
合作者和调查者
调查人员
- 首席研究员:Paul Leeson, PhD, FRCP、University of Oxford Department of Cardiovascular Medicine
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.